← Back to headlines
Piper Sandler Reaffirms Moderna Stock Rating Following Flu Vaccine Approval
Piper Sandler has reiterated its stock rating for Moderna after the company received approval for its flu vaccine.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
